KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis
FRA:PHI1 - Deutsche Boerse Ag - NL0000009538 - Common Stock - Currency: EUR
Overall PHI1 gets a fundamental rating of 3 out of 10. We evaluated PHI1 against 55 industry peers in the Health Care Equipment & Supplies industry. PHI1 has a bad profitability rating. Also its financial health evaluation is rather negative. PHI1 has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year PHI1 was profitable.
PHI1 had a positive operating cash flow in the past year.
In multiple years PHI1 reported negative net income over the last 5 years.
PHI1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -2.42%, PHI1 perfoms like the industry average, outperforming 43.64% of the companies in the same industry.
PHI1 has a Return On Equity (-5.85%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.42% | ||
| ROE | -5.85% | ||
| ROIC | N/A |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHI1's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 43.13%, PHI1 is not doing good in the industry: 67.27% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of PHI1 has remained more or less at the same level.
PHI1 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.13% |
OM growth 3Y-2.25%
OM growth 5Y-8.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
2. Health
2.1 Basic Checks
PHI1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
PHI1 has less shares outstanding than it did 1 year ago.
PHI1 has more shares outstanding than it did 5 years ago.
PHI1 has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.71, we must say that PHI1 is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.71, PHI1 perfoms like the industry average, outperforming 52.73% of the companies in the same industry.
PHI1 has a debt to FCF ratio of 8.68. This is a slightly negative value and a sign of low solvency as PHI1 would need 8.68 years to pay back of all of its debts.
The Debt to FCF ratio of PHI1 (8.68) is comparable to the rest of the industry.
PHI1 has a Debt/Equity ratio of 0.59. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.59, PHI1 is not doing good in the industry: 61.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.59 | ||
| Debt/FCF | 8.68 | ||
| Altman-Z | 1.71 |
ROIC/WACCN/A
WACC6.21%
2.3 Liquidity
A Current Ratio of 1.23 indicates that PHI1 should not have too much problems paying its short term obligations.
PHI1 has a Current ratio of 1.23. This is in the lower half of the industry: PHI1 underperforms 61.82% of its industry peers.
PHI1 has a Quick Ratio of 1.23. This is a bad value and indicates that PHI1 is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.84, PHI1 perfoms like the industry average, outperforming 41.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
PHI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.37%, which is quite good.
PHI1 shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.07% yearly.
The Revenue has decreased by -0.82% in the past year.
Measured over the past years, PHI1 shows a small growth in Revenue. The Revenue has been growing by 1.00% on average per year.
EPS 1Y (TTM)12.37%
EPS 3Y-5.48%
EPS 5Y-7.07%
EPS Q2Q%26.36%
Revenue 1Y (TTM)-0.82%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%1.98%
3.2 Future
The Earnings Per Share is expected to grow by 15.81% on average over the next years. This is quite good.
The Revenue is expected to grow by 5.73% on average over the next years.
EPS Next Y11.88%
EPS Next 2Y13.66%
EPS Next 3Y13.18%
EPS Next 5Y15.81%
Revenue Next Year3.9%
Revenue Next 2Y4.18%
Revenue Next 3Y4.38%
Revenue Next 5Y5.73%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 18.14, the valuation of PHI1 can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of PHI1 indicates a rather cheap valuation: PHI1 is cheaper than 83.64% of the companies listed in the same industry.
PHI1's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 29.35.
PHI1 is valuated correctly with a Price/Forward Earnings ratio of 16.18.
Based on the Price/Forward Earnings ratio, PHI1 is valued a bit cheaper than 72.73% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of PHI1 to the average of the S&P500 Index (22.10), we can say PHI1 is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.14 | ||
| Fwd PE | 16.18 |
4.2 Price Multiples
PHI1's Enterprise Value to EBITDA is on the same level as the industry average.
PHI1's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PHI1 is cheaper than 81.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.94 | ||
| EV/EBITDA | 20.96 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as PHI1's earnings are expected to grow with 13.18% in the coming years.
PEG (NY)1.53
PEG (5Y)N/A
EPS Next 2Y13.66%
EPS Next 3Y13.18%
5. Dividend
5.1 Amount
PHI1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:PHI1 (3/7/2025, 7:00:00 PM)
25.22
-0.04 (-0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners48.26%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap23.71B
Analysts73.33
Price Target29 (14.99%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)-70.49%
DP-0.14%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.57%
Min EPS beat(2)-16.56%
Max EPS beat(2)-10.58%
EPS beat(4)0
Avg EPS beat(4)-11.81%
Min EPS beat(4)-16.56%
Max EPS beat(4)-6.96%
EPS beat(8)2
Avg EPS beat(8)0.96%
EPS beat(12)3
Avg EPS beat(12)3.42%
EPS beat(16)5
Avg EPS beat(16)1.26%
Revenue beat(2)0
Avg Revenue beat(2)-2.99%
Min Revenue beat(2)-5.22%
Max Revenue beat(2)-0.76%
Revenue beat(4)0
Avg Revenue beat(4)-2.85%
Min Revenue beat(4)-5.22%
Max Revenue beat(4)-0.76%
Revenue beat(8)1
Avg Revenue beat(8)-2.36%
Revenue beat(12)2
Avg Revenue beat(12)-1.5%
Revenue beat(16)2
Avg Revenue beat(16)-2.3%
PT rev (1m)0.29%
PT rev (3m)0.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)27.32%
EPS NY rev (1m)0.81%
EPS NY rev (3m)-6.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.13%
Revenue NY rev (1m)-0.65%
Revenue NY rev (3m)-1.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.14 | ||
| Fwd PE | 16.18 | ||
| P/S | 1.32 | ||
| P/FCF | 26.94 | ||
| P/OCF | 15.23 | ||
| P/B | 1.97 | ||
| P/tB | N/A | ||
| EV/EBITDA | 20.96 |
EPS(TTM)1.39
EY5.51%
EPS(NY)1.56
Fwd EY6.18%
FCF(TTM)0.94
FCFY3.71%
OCF(TTM)1.66
OCFY6.56%
SpS19.17
BVpS12.77
TBVpS-1.45
PEG (NY)1.53
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.42% | ||
| ROE | -5.85% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.13% | ||
| FCFM | 4.88% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.25%
OM growth 5Y-8.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
F-Score6
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.59 | ||
| Debt/FCF | 8.68 | ||
| Debt/EBITDA | 5.15 | ||
| Cap/Depr | 48.63% | ||
| Cap/Sales | 3.75% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 112.67% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z | 1.71 |
F-Score6
WACC6.21%
ROIC/WACCN/A
Cap/Depr(3y)50.01%
Cap/Depr(5y)53.78%
Cap/Sales(3y)3.94%
Cap/Sales(5y)4.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.37%
EPS 3Y-5.48%
EPS 5Y-7.07%
EPS Q2Q%26.36%
EPS Next Y11.88%
EPS Next 2Y13.66%
EPS Next 3Y13.18%
EPS Next 5Y15.81%
Revenue 1Y (TTM)-0.82%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%1.98%
Revenue Next Year3.9%
Revenue Next 2Y4.18%
Revenue Next 3Y4.38%
Revenue Next 5Y5.73%
EBIT growth 1Y91.51%
EBIT growth 3Y-0.63%
EBIT growth 5Y-7.54%
EBIT Next Year67.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-45.51%
FCF growth 3Y-40.93%
FCF growth 5Y-1.73%
OCF growth 1Y-31.12%
OCF growth 3Y-32.38%
OCF growth 5Y-4.03%